Andrew Blight, Chief Scientific Officer at ACORDA THERAPEUTICS INC (ACOR), sold 7,000 shares at $32.34 ($226K) on 2008-06-05, disclosed to the SEC on 2008-06-09.
Scheduled sale ($226k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.04 | 100 | $3K | 1.4% |
| 2 | $32.05 | 300 | $10K | 4.3% |
| 3 | $32.08 | 200 | $6K | 2.8% |
| 4 | $32.09 | 300 | $10K | 4.3% |
| 5 | $32.10 | 200 | $6K | 2.8% |
| 6 | $32.11 | 100 |
| $3K |
| 1.4% |
| 7 | $32.12 | 100 | $3K | 1.4% |
| 8 | $32.13 | 100 | $3K | 1.4% |
| 9 | $32.14 | 100 | $3K | 1.4% |
| 10 | $32.15 | 300 | $10K | 4.3% |
| 11 | $32.16 | 100 | $3K | 1.4% |
| 12 | $32.17 | 100 | $3K | 1.4% |
| 13 | $32.18 | 100 | $3K | 1.4% |
| 14 | $32.20 | 300 | $10K | 4.3% |
| 15 | $32.22 | 100 | $3K | 1.4% |
| 16 | $32.24 | 164 | $5K | 2.3% |
| 17 | $32.25 | 100 | $3K | 1.4% |
| 18 | $32.26 | 100 | $3K | 1.4% |
| 19 | $32.28 | 400 | $13K | 5.7% |
| 20 | $32.29 | 300 | $10K | 4.3% |
| 21 | $32.30 | 400 | $13K | 5.7% |
| 22 | $32.31 | 200 | $6K | 2.9% |
| 23 | $32.32 | 300 | $10K | 4.3% |
| 24 | $32.33 | 800 | $26K | 11.5% |
| 25 | $32.34 | 200 | $6K | 2.9% |
| 26 | $32.35 | 600 | $19K | 8.6% |
| 27 | $32.36 | 436 | $14K | 6.2% |
| 28 | $32.37 | 500 | $16K | 7.2% |
| Total | $32.25 avg | 7,000 | $226K | 100% |
| Filing → |
| ACOR | SELL | 2015-11-23 | $19K | — | Filing → |
| ACOR | SELL | 2015-10-21 | $1.0M | — | Filing → |
| ACOR | SELL | 2015-09-23 | $410K | — | Filing → |